These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 11429122

  • 1. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV, Huismans R, Jebbink MF, Danner SA, de Boer RJ, Goudsmit J.
    AIDS Res Hum Retroviruses; 2001 Jun 10; 17(9):807-18. PubMed ID: 11429122
    [Abstract] [Full Text] [Related]

  • 2. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W, Matsuda M, Matsuda Z, Abumi H, Okano A, Oishi T, Moriya K, Yamamoto Y, Fukutake K, Mimaya J, Ajisawa A, Taki M, Yamada K, Nagai Y.
    J Hum Virol; 1999 Jun 10; 2(3):146-53. PubMed ID: 10413366
    [Abstract] [Full Text] [Related]

  • 3. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
    J Virol; 2004 Jul 10; 78(14):7545-52. PubMed ID: 15220429
    [Abstract] [Full Text] [Related]

  • 4. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 10; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 5. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
    de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J.
    J Virol; 2001 Jan 10; 75(2):595-602. PubMed ID: 11134272
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.
    Virology; 2001 May 10; 283(2):294-305. PubMed ID: 11336554
    [Abstract] [Full Text] [Related]

  • 12. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.
    J Acquir Immune Defic Syndr; 2000 Dec 15; 25(5):465-6. PubMed ID: 11141248
    [No Abstract] [Full Text] [Related]

  • 13. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L, Back N, Jebbink MF, de Ronde A, Bakker M, Jurriaans S, Reiss P, Parkin N, Berkhout B.
    J Virol; 2005 Mar 15; 79(6):3536-43. PubMed ID: 15731248
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA, Leriche-Guerin K, Regis C, Bordes I, Cotte L, Detmer J, Kolberg J, Ritter J, Trépo C.
    J Med Virol; 2000 Jul 15; 61(3):352-9. PubMed ID: 10861645
    [Abstract] [Full Text] [Related]

  • 15. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.
    Milazzo L, Rusconi S, Testa L, La Seta-Catamancio S, Galazzi M, Kurtagic S, Citterio P, Gianotto M, Grassini A, Adorni F, d'Arminio-Monforte A, Galli M, Moroni M.
    J Acquir Immune Defic Syndr; 1999 Sep 01; 22(1):101-3. PubMed ID: 10534153
    [No Abstract] [Full Text] [Related]

  • 16. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
    Cabana M, Clotet B, Martínez MA.
    J Med Virol; 1999 Dec 01; 59(4):480-90. PubMed ID: 10534730
    [Abstract] [Full Text] [Related]

  • 17. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY, Vrang L, Oberg B, Merigan TC.
    AIDS Res Hum Retroviruses; 2001 Mar 20; 17(5):401-7. PubMed ID: 11282008
    [Abstract] [Full Text] [Related]

  • 18. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L, Johnson M, Graham N, Shaefer M, St Clair M.
    J Hum Virol; 1999 Mar 20; 2(5):290-5. PubMed ID: 10551735
    [Abstract] [Full Text] [Related]

  • 19. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F.
    Antivir Ther; 2007 Mar 20; 12(3):335-43. PubMed ID: 17591023
    [Abstract] [Full Text] [Related]

  • 20. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
    Krebs R, Immendörfer U, Thrall SH, Wöhrl BM, Goody RS.
    Biochemistry; 1997 Aug 19; 36(33):10292-300. PubMed ID: 9254628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.